Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24989032 | 0.91 | GPR119 (0.56) | CHRM4ALDH1A1LMNAMAPTPDK2 | |
| SCHEMBL6269762 | 0.91 | GPR119 (0.57) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL31474292 | 0.91 | GPR119 (0.57) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL24216718 | 0.88 | MAPT (0.52) | CHRM4ALDH1A1LMNAMAPTPDK2 | |
| SCHEMBL15938198 | 0.86 | MAPT (0.55) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL30126546 | 0.86 | MAPT (0.55) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL31342407 | 0.86 | MAPT (0.53) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL20159003 | 0.85 | MAPT (0.59) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL24990173 | 0.84 | MAPT (0.53) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL24990143 | 0.84 | GPR119 (0.67) | ALDH1A1LMNAMAPTPDK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114674-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4095132-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021147889-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 康朴生物医药技术（上海）有限公司 | 2021-07-29 | — | — | WO | disclosed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089493-A1 | PYRROLE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114674-A1 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CRBN, CREBBP, CDR2 | CHRM4 3413/4885ALDH1A1 3179/4885LMNA 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.